[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mutation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,88,134,166,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100559428","phase-2-neoadjuvant-umbrella-trial-for-patients-with-unresectable-stage-iii-nsclc-harboring-rare-mutations-100559428",false,"NCT06563999","Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.","Neoadjuvant Umbrella Trial Directed by Next Generation Sequencing for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations (Without EGFR Sensitizing Mutations)","NUMER","Inclusion Criteria:\n\n* Subjects must have treatment-naive unresectable stage III NSCLC according to the AJCC 8th edition staging;\n* Squamous or non-squamous NSCLC histology;\n* Subjects should have a rare mutation based on NGS, including mutations of EGFR exon20ins, ROS1 fusion, RET fusion, NTRK fusion, MET 14 exon, HER2, BRAF V600E, KRAS G12C, and ALK fusion.\n* Subjects should be without EGFR exon 19 deletions or exon 21 L858R activating mutation;\n* Male and female, aged 18-75 years;\n* Blood and specimens before and after treatment must be provided;\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n* Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109\u002FL, and Platelet count ≥100 x 109\u002FL, and Hemoglobin ≥9 g\u002FdL (may be transfused to maintain or exceed this level);\n* Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN;\n* Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml\u002Fmin;\n* Female subjects should not be pregnant or breast-feeding;\n* Written informed consent provided. Being willing and able to comply with the visits, treatment plan, laboratory examinations and other study procedures scheduled in the study.\n\nExclusion Criteria:\n\n* Not unresectable stage III disease according to the investigator;\n* Subjects with known EGFR sensitive mutations;\n* Previous treatment with systemic antitumor therapy for NSCLC;\n* Eye inflammation or eye infection not fully treated or conditions predisposing the subject to this.\n* History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.\n* Evidence of clinically active interstitial lung disease;\n* Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);\n* Inability to comply with protocol or study procedures;\n* Any unstable systemic disease (including active infection, active tuberculosis uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease);\n* A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study and may confuse the study results;\n* Women who are pregnant or nursing.\n* Ingredients mixed with small cell lung cancer patients.","ALL","18 Years","75 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC). The aim of the umbrella study is to evaluate the efficacy of induction NGS-directed targeted therapies followed by surgery for stage III NSCLC patients whose tumor harbors a rare mutation.",[28,29],"Lung Cancer Stage III","Mutation",[31,32,33,34],"stage III NSCLC","rare mutations","umbrella trial","neoadjuvant","RECRUITING","2026-04-19",{"date":38,"type":39},"2026-04-21","ACTUAL",{"date":41,"type":39},"2024-11-01",{"date":43,"type":22},"2029-11-01",{"name":45,"class":46},"Sun Yat-sen University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":71,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":47},"100599518","natural-history-study-of-inherited-retinal-diseases-100599518","NCT07085533","Natural History Study of Inherited Retinal Diseases","Color Vision Loss Progression in IRD Patients: Retinal Structural Changes Correlations, and a Novel Color Discrimination Test for Extreme Low Vision Patients","MojiLVCDT","Inclusion Criteria:\n\n1. Color Perception and Communication Ability Participants must have the ability to verbally identify or describe colors and test stimuli. This requires adequate cognitive and communicative capacity to understand instructions and respond appropriately during color vision testing.\n2. Diagnosis of Inherited Retinal Dystrophy (IRD Group Only) Participants assigned to the IRD group must have a confirmed clinical diagnosis of an inherited retinal dystrophy\n3. No Evidence of Inherited Retinal Disease (Control Group Only)\n\nParticipants in the control group must have:\n\n* No known history or clinical evidence of inherited retinal degeneration\n* Normal retinal health or only non-retinal ocular conditions not affecting retinal function (e.g., mild cataract, corrected refractive error)\n* Normal or expected-normal color vision\n\nExclusion Criteria:\n\n1. Non retinal causes of color vision loss\n\n   * Optic neuropathies (e.g., optic neuritis, glaucoma related optic nerve damage)\n   * Cortical vision impairments affecting color perception\n   * Any other neurological or optic nerve pathology causing color vision deficiency\n2. Psychological or cognitive conditions affecting color perception or communication\n\n   * Severe developmental delays\n   * Cognitive impairments interfering with ability to comprehend or reliably perform color vision tests\n   * Psychiatric conditions that impair visual interpretation or reliable testing\n3. Prior treatment with potential transient effects on the retina\n\n   * Recent retinal surgery\n   * Recent drug therapy affecting retinal structure or function\n   * Any acute intervention that might confound the correlation analyses due to lack of a stable baseline",true,{"count":58,"type":22},200,"OBSERVATIONAL","This prospective, observational investigation seeks to delineate the interplay between chromatic vision deficits and both functional visual outcomes and anatomical retinal biomarkers in individuals affected by Inherited Retinal Dystrophies (IRDs). The study will recruit approximately 200 subjects, encompassing a heterogeneous population of IRD patients-spanning a range of genotypes and clinical severities-as well as control participants devoid of retinal pathology. All enrolled individuals will undergo a standardized battery of evaluations, including quantitative color vision assessment, best-corrected visual acuity (BCVA) determination, and advanced multimodal retinal imaging.\n\nThe principal aim is to characterize the relationship between impairments in color discrimination and morphologic disruptions within the outer retinal layers, with particular emphasis on the continuity and reflectivity of the ellipsoid zone (EZ)-historically referred to as the inner segment\u002Fouter segment (IS\u002FOS) junction-assessed through spectral-domain optical coherence tomography (SD-OCT). Further, the study will explore associations between chromatic perceptual deficits and underlying genetic mutations, mutation patterns specific to IRD subtypes, and the influence of patient age on the severity and progression of color vision loss.\n\nA key secondary objective is the clinical appraisal and validation of a novel diagnostic modality, the Moji Low-Vision Color Discrimination Test (Moji Test), which is specifically engineered to quantify residual color perception in individuals with advanced central visual impairment. The test's discriminatory capacity will be benchmarked against established color vision testing paradigms to assess its reliability, clinical sensitivity, and suitability for implementation in populations with severe visual acuity reduction.\n\nBy incorporating a genetically and phenotypically diverse IRD cohort, the study is designed to enable granular, stratified analyses that will refine the understanding of structural-functional correlations in hereditary retinal disease. The inclusion of a control group with preserved retinal architecture and normal color vision function will provide essential normative baselines for comparative evaluation and statistical inference.",[62,63,64,65,66,67,68,69,29,70],"Retinal Dystrophies","Color Vision Defects","Vision Disorders","Macular Degeneration","Achromatopsia","Optical Coherence Tomography (OCT)","Visual Acuity","Genotype","Phenotype",[72,73,74,75,76,77],"observational","IRD","ultra low vision","inherited retinal disease","color vision","color test","2025-12-03",{"date":80,"type":39},"2025-12-10",{"date":82,"type":39},"2025-07-20",{"date":84,"type":22},"2027-09-28",{"name":86,"class":87},"Zhongmou Therapeutics","INDUSTRY",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":97,"conditions":98,"keywords":116,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":47},"100339653","liquid-biopsy-evaluation-and-repository-development-at-princess-margaret-100339653","NCT03702309","Liquid Biopsy Evaluation and Repository Development at Princess Margaret","LIBERATE","Inclusion Criteria:\n\n1. Patients with either histological confirmation of a solid tumor or hematological malignancy, OR patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and\u002For family history without known aberration).\n2. Patient must be ≥ 18 years old.\n3. All patients must have signed and dated an informed consent form for this LIBERATE study.\n4. If patients are being co-consented for a separate primary research study listed in Appendix I, they must fulfill the eligibility criteria for that separate primary research study. If there is a discrepancy in the eligibility criteria between protocols, the separate primary research study's criteria take precedence.\n\nExclusion Criteria:\n\nNone",{"count":96,"type":22},2500,"The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples (\"liquid biopsies\") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.",[99,100,101,102,103,104,105,106,29,107,108,109,110,111,112,113,114,115],"Cancer","Breast Cancer","Lung Cancer","Colon Cancer","Ovarian Cancer","Melanoma","Lymphoma","Leukemia","Lynch Syndrome","Cowden Syndrome","BRCA1 Mutation","BRCA2 Mutation","Uterine Cancer","Myeloma","Kidney Cancer","Head and Neck Cancer","Meningioma",[117,118,119,120,121,122,123,124],"High Risk","Liquid Biopsy","Circulating Tumor DNA","Blood","Molecular Profiling","Next Generation Sequencing","Solid Tumors","Hematological","2025-11-25",{"date":127,"type":39},"2025-11-26",{"date":129,"type":39},"2017-08-03",{"date":131,"type":22},"2026-07-06",{"name":133,"class":46},"University Health Network, Toronto",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":143,"conditions":144,"keywords":151,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":47},"100504435","natural-history-study-of-patients-with-hpdl-mutations-100504435","NCT05848271","Natural History Study of Patients with HPDL Mutations","A Patient Registry and Natural History Study of Patients with Biallelic HPDL Mutations","Inclusion Criteria:\n\n* Any individuals diagnosed with HPDL variants\n* Clinical diagnosis can include:\n\n  * HPDL-related hereditary spastic paraplegia (HSP)\n  * HPDL-related neonatal mitochondrial encephalopathy\n  * Spastic paraplegia -83 (SPG83)\n  * Neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities (NEDSWMA)\n\nExclusion Criteria:\n\n* Any known genetic abnormality (other than HPDL mutation)\n* Any condition that, in the opinion of the Site Investigator, could put the participant at undue risk and\u002For would ultimately prevent the completion of study procedures",{"count":142,"type":22},50,"This study uses medical records that allow retrospective data extraction of clinical manifestation to assess the natural history of HPDL mutations",[145,146,147,148,149,29,150],"Mitochondrial Encephalomyopathies","Hereditary Spastic Paraplegia","Spastic Paraplegia","White Matter Disease","Neonatal Encephalopathy","Genetic Disease",[152,153,154,155,156],"HPDL","HPDL related neonatal mitochondrial encephalopathy","HPDL related hereditary spastic paraplegia","Spastic paraplegia-83","Neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities","2025-03-25",{"date":159,"type":39},"2025-03-30",{"date":161,"type":39},"2023-05-18",{"date":163,"type":22},"2027-12-31",{"name":165,"class":46},"University of California, San Diego",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":176,"conditions":177,"keywords":182,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":201},"100473535","biomel--diagnostic-and-prognostic-factors-in-melanoma-100473535","NCT05446155","BioMEL- Diagnostic and Prognostic Factors in Melanoma.","BioMEL - a Translational Study About Aetiology, Diagnosis, Prognosis, Treatment, Biology and Biomarkers in Clinically Atypical Nevi and Melanoma.","BioMEL","Inclusion Criteria:\n\n* Primary part of the project: Patients in dermatological outpatient routine care in Helsingborg, Lund or Malmö Hospitals. Patients are planned for surgical excision for an equivocal pigmented skin lesion that could be a primary melanoma or a differential diagnosis of melanoma\n* Secondary part of the project: . Patient, in surgical or oncological routine care in Helsingborg, Lund, Malmö or Kristianstad Hospitals. Patients are planned for surgical excision or cytological diagnostics (needle aspiration) of metastatic melanoma.\n* All subjects have to be able to provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with lesions, primary or secondary, that are so small that a punch biopsy for the study would risk affecting the histopathological diagnosis.",{"count":175,"type":22},2000,"The investigators' hypothesis is that cutaneous melanoma, melanoma in situ, dysplastic nevi and benign nevi all differ in not only clinical characteristics but also molecular and genotypic characteristics.\n\nPatients with suspected primary cutaneous melanoma or a differential diagnosis, or secondary melanoma can be asked to participate in the first part of the project and patients with suspected or confirmed secondary (spread) melanoma can be included in the second part of the study. Participants included in the study answer a validated questionnaire regarding epidemiological and phenotypic factors to map medical history, prior UV exposure, family history of melanoma and\u002For other cancer types, skin type, smoking habits, alcohol use and quality of life.\n\nBlood samples (whole blood) are collected before primary local excision and before secondary surgical procedures as well as during follow up of patients with secondary disease and oncologic treatment. During local excision of the primary pigmented skin lesion, full-thickness skin punch biopsies are taken by trained dermatologists. The biopsies, in the lesion and next to the lesion in the normal skin of the suspected melanoma, are taken, snap frozen and stored deep frozen. The primary lesions are documented by accurate imaging methods prior to excision.\n\nTissue samples from suspected or confirmed secondary melanomas are collected mainly through surgical and core needle biopsies before, during and after treatment and in case of disease progress or treatment failure. Tissue samples are snap-frozen and stored in the same way as samples from primary melanomas.\n\nComprehensive questionnaire based, imaging-based information, as well as histologic information provided from the pathologist report is included and stored in a secure database.\n\nAll the information in the database, along with information from molecular analysis of tissue and\u002For blood samples will then be used to find objective, molecular and clinical differences in melanoma, melanoma in situ, dysplastic and benign nevi along with potential information of biological aggressivity of both primary and secondary melanoma in order to find more objective diagnostic markers.",[104,178,179,180,181,29],"Melanoma in Situ","Dysplastic Nevi","Mole (Dermatology)","Image",[183,104,184,185,186,187,188,189,190,191],"Biobank","nevus","mole","dermoscopy","dermatoscopy","skin cancer","Sequence analysis, DNA","Sequence analysis, RNA","Whole genome sequencing","2024-01-22",{"date":194,"type":39},"2024-01-23",{"date":196,"type":39},"2013-11-04",{"date":198,"type":22},"2028-12",{"name":200,"class":46},"Region Skane",4,{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":210,"minAge":18,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":216,"conditions":217,"keywords":220,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":47},"100512591","phase-3-everolimus-with-investigators-choice-of-chemotherapy-in-advanced-triple-negative-breast-cancer-tnbc-with-luminal-androgen-receptor-lar-subtype-100512591","NCT05954442","Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype","An Open, Randomized Phase III Study of Everolimus With Investigator's Choice of Chemotherapy Versus Chemotherapy in The First-Line Treatment of Luminal Androgen Receptor (LAR) Subtype With PI3K\u002FAKT\u002FmTOR Pathway Mutation of Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (BCTOP-T-M03)","BCTOP-T-M03","Inclusion Criteria:\n\n* Patients need to meet all of the following conditions\n\n  * Patients must be ≥18 and ≤ 70 years of age;\n  * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;\n  * The expected survival is more than 3 months;\n  * Pathologically confirmed breast cancer is triple negative breast cancer (IHC ER \\\u003C 1%, PR\\\u003C1%, HER2 0 OR +, if HER2++, FISH negative), and LAR subtype with mutation in PAM pathway;\n  * Recurrent or metastatic breast cancer; Patients with local recurrence need to be confirmed by the investigator that radical surgical resection is not possible;.\n  * No prior therapy (chemotherapy, targeted therapy, etc.) for advanced or metastatic breast cancer;\n  * Patients with at least one lesion (measurable and\u002For unmeasurable) that has not previously received radiation therapy can be accurately evaluated by CT\u002FMRI at baseline and can be evaluated repeatedly according to RECIST 1.1;\n  * The functions of the main organs are basically normal, and the following conditions are met:\n\n    1. Blood routine examination standards should meet: HB≥90g\u002FL (no blood transfusion within 14 days); ANC≥1.5×109\u002FL; PLT≥75×109\u002FL;\n    2. Biochemical examination shall meet the following standards: TBIL≤1.5× upper limit of normal value(ULN); alanine aminotransferase (ALT) and AST≤3 x ULN; In case of liver metastasis, ALT and AST≤5×ULN; Serum Cr ≤1×ULN, endogenous creatinine clearance \\> 50ml\u002Fmin (Cockcroft-Gault formula);\n  * Patients have not received radiotherapy, endocrine therapy, molecular targeted therapy, or surgery within 3 weeks prior to study initiation, and have recovered from acute toxic effects of prior treatment (if surgery is present, the wound has fully healed); No peripheral neuropathy or grade I peripheral neurotoxicity;\n  * Fertile female are required to use a medically approved contraceptive during study treatment and for at least 3 months after the last use of the study drug;\n  * Patients voluntarily join the study, sign the informed consent, have good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n* Patients with any of the following conditions were excluded from the study:\n\n  * Patients with known central nervous system metastasis or history of central nervous system metastasis prior to screening. For patients with clinically suspected central nervous system metastasis, enhanced CT or enhanced MRI must be performed within 28 days before the first dose to rule out central nervous system metastasis.\n  * A history of clinically significant or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction within the last 6 months, or ventricular arrhythmia;\n  * Persistent grade ≥1 adverse events due to previous treatment. The exception to this is hair loss or something the researchers believe should not be ruled out. Such cases should be clearly documented in the investigator's notes;\n  * Major surgery was performed within 3 weeks of the first course of trial treatment (except for minor outpatient surgery, such as placement of vascular access);\n  * Pregnant or lactating patients;\n  * Other malignancies within the previous 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, or skin squamous cell carcinoma;\n  * Inability to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug use and absorption;\n  * There is a third space effusion that cannot be controlled by drainage or other methods (such as excessive pleural fluid and ascites);\n  * Participated in other anti-tumor drug clinical trials within 4 weeks before taking the study drug for the first time;\n  * Long-term unhealed wounds or incomplete healing fractures;\n  * Patients with known Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection active phase or hepatitis B DNA≥500, or chronic phase with abnormal liver function;\n  * Allergic physique, or known allergic history of the drug components of this program; Or allergic to other monoclonal antibodies;\n  * The investigator does not consider the patient suitable for participation in any other circumstances of the study.","FEMALE","70 Years",{"count":213,"type":22},203,[215],"PHASE3","The goal of this clinical trial is to evaluate the efficacy of investigator's choice of chemotherapy, either alone or in combination with everolimus, in treating patients with locally recurrent inoperable or metastatic triple-negative breast cancer, luminal androgen receptor (LAR) subtype with PI3K\u002FAKT\u002FmTOR (PAM) pathway mutation, as the first-line treatment.",[218,219,29],"Triple Negative Breast Cancer","Metastatic Breast Cancer",[221,222,223],"triple negative breast cancer","metastatic breast cancer","PI3K\u002FAKT\u002FmTOR mutation","2024-01-12",{"date":226,"type":39},"2024-01-16",{"date":228,"type":39},"2023-09-13",{"date":230,"type":22},"2026-08",{"name":232,"class":46},"Fudan University"]